This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pertussis vaccine
DrugBank Accession Number
DB15274
Background

Pertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Bordetella pertussis

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Pertussis Vaccine 4 Protect UnitSuspension15000 m / mLSubcutaneousAventis Pasteur Limited1921-12-312001-07-19Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Diphtheria and Tetanus Toxoids With Pertussis Vaccine AdsorbedPertussis vaccine (12 unit / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf / 0.5 mL)LiquidIntramuscularAventis Pasteur Limited1980-12-312001-07-19Canada flag
Infanrix HexaPertussis vaccine (25 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPertussis vaccine (25 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPertussis vaccine (25 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPertussis vaccine (25 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPertussis vaccine (25 µg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
INFANRIX HEXA (DPTA - HEPB - IPV - HIB).Pertussis vaccine (25 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis pertactin antigen (8 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (25 mcg) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 UD) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 UD) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 UD)SuspensionIntramuscularGLAXO SMITHKLINE BIOLOGICALS NL DER SMITHKLINE BEECHAM PHARMA GMBH & CO.KG2006-11-10Not applicableColombia flag
Tri-immunol Liq ImPertussis vaccine (4 unit / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (12.5 lf / 0.5 mL)LiquidIntramuscularLederle Labs, Division of American Cyanamid Co1993-12-312001-06-05Canada flag
ทริพแวคPertussis vaccine (4 IU/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (60 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml)Injection, suspensionบริษัท ไบโอจีนีเทค จำกัด2019-02-26Not applicableThailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2QNL82089R
CAS number
Not Available

References

General References
Not Available
RxNav
1608803
Wikipedia
Pertussis_vaccine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionHuman Papilloma Virus-Related Cervical Carcinoma / Human Papillomavirus Infections1
4CompletedPreventionDiphtheria / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Tetanus / Whooping Cough2
4CompletedPreventionFebrile Convulsions / Fever / Fever After Vaccination1
4CompletedPreventionHealthy Subjects (HS)1
4CompletedPreventionInfluenza, Human1
4CompletedPreventionMeningococcal Meningitis1
4CompletedPreventionPertussis / Pregnant State1
4CompletedPreventionPregnant State1
4RecruitingPreventionApnea / Apnoea neonatal / Infants, Premature1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, solutionIntramuscular
LiquidIntramuscular
Injection, suspensionParenteral
SuspensionIntramuscular
Injection, powder, for suspensionIntramuscular
InjectionIntramuscular
SuspensionSubcutaneous15000 m / mL
Injection, suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 15:06 / Updated at January 24, 2021 06:04